School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
J Med Econ. 2022 Jan-Dec;25(1):966-973. doi: 10.1080/13696998.2022.2096892.
For hospitalized patients with chronic obstructive pulmonary disease (COPD), albuterol and levalbuterol can both be used as relievers to alleviate bronchoconstriction. This study aimed to evaluate levalbuterol and albuterol's cost-utility and budget impact in hospitalized patients with COPD.
A cost-utility analysis was used to evaluate the impact on the costs of nebulized levalbuterol verse albuterol in hospitalized patients with COPD. The decision tree model was employed to estimate the incremental cost per quality-adjusted life year in the admission setting. A budget impact model was used to examine the impact of budget on levalbuterol's entry into the Chinese market from the healthcare system's perspective. One-way sensitivity and probabilistic sensitivity analyses were performed to test the uncertainty of the parameters.
The cost-utility results showed that levalbuterol saved ¥495.7 ($105.1) per hospitalization, while the budget impact analysis revealed a potential saving of ¥22.3 ($6.8) million in 3 years. The sensitivity analysis indicated that the results were robust to the changes in input parameter values.
Levalbuterol is a cost-saving option for treating hospitalized patients with COPD in China.
对于住院的慢性阻塞性肺疾病（COPD）患者，沙丁胺醇和左旋沙丁胺醇均可作为缓解剂来缓解支气管痉挛。本研究旨在评估住院 COPD 患者中左旋沙丁胺醇和沙丁胺醇的成本-效用和预算影响。
采用成本-效用分析评估住院 COPD 患者中雾化用左旋沙丁胺醇相对于沙丁胺醇的成本影响。采用决策树模型估算入院环境下每增加一个质量调整生命年的增量成本。采用预算影响模型从医疗保健系统的角度考察左旋沙丁胺醇进入中国市场的预算影响。进行了单因素敏感性分析和概率敏感性分析以检验参数的不确定性。
成本-效用结果显示，住院期间左旋沙丁胺醇可节省 495.7 元人民币（105.1 美元），而预算影响分析显示，3 年内可能节省 2230 万元人民币。敏感性分析表明，结果对输入参数值的变化具有稳健性。
在中国，治疗住院 COPD 患者时，左旋沙丁胺醇是一种具有成本效益的选择。
